Compare DV & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DV | DNTH |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2021 | N/A |
| Metric | DV | DNTH |
|---|---|---|
| Price | $10.99 | $42.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | $16.56 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 2.3M | 756.3K |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $733,324,000.00 | $3,078,000.00 |
| Revenue This Year | $17.93 | N/A |
| Revenue Next Year | $10.74 | N/A |
| P/E Ratio | $41.60 | ★ N/A |
| Revenue Growth | ★ 14.86 | N/A |
| 52 Week Low | $7.64 | $13.37 |
| 52 Week High | $23.11 | $45.46 |
| Indicator | DV | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 54.91 |
| Support Level | $10.83 | $42.70 |
| Resistance Level | $11.26 | $44.06 |
| Average True Range (ATR) | 0.27 | 1.74 |
| MACD | 0.10 | -0.39 |
| Stochastic Oscillator | 73.85 | 28.78 |
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.